Valorising and creating access to innovative medicines in the European Union

Frontiers in Pharmacology

Volumn OCT, Issue , 2011, Pages

  Annemans, Lieven ^a   Cleemput, Irina ^b   Hulstaert, Frank ^b   Simoens, Steven ^c  

^a GHENT UNIVERSITY   (Belgium)

^b BELGIAN HEALTH CARE KNOWLEDGE CENTRE KCE   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Access; Budget impact; Cost effectiveness; Health technology assessment; Medical need; Pharmaceutical innovation; Relative effectiveness

Indexed keywords

BORTEZOMIB; FINASTERIDE; RISEDRONIC ACID; SITAGLIPTIN; VALSARTAN; VARDENAFIL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BUDGET; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MANUFACTURE; DRUG MARKETING; DRUG SAFETY; ERECTILE DYSFUNCTION; EUROPEAN UNION; HEALTH CARE ACCESS; HEALTH CARE AVAILABILITY; HEALTH CARE NEED; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE SYSTEM; HEALTH TECHNOLOGY ASSESSMENT; HUMAN; MEDICINE; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PERFORMANCE BASED AGREEMENT; PRACTICE GUIDELINE; PROSTATE HYPERTROPHY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; UNCERTAINTY;

EID: 84865959325     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2011.00057     Document Type: Article

References (22)

1. Carlson, J. J., Garrison, L. P., and Sullivan, S. D. (2009). Paying for outcomes: innovative coverage and reimbursement schemes for phar- maceuticals. J. Manag. Care Pharm. 15, 683-687.
2. Cleemput, I., Neyt, M., Thiry, N., De Laet,C.,and Leys,M. (2008).Thresh- old Values for Cost-Effectiveness in Health Care. Brussels: Bel- gian Health Care Knowledge Centre.
3. Clement, F. M., Harris, A., Li, J. J., Yong, K., Lee, K. M., and Manns, B. J. (2009). Using effectiveness and cost- effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 302, 1437-1443.
4. Docteur, E., and Paris, V. (2008). Improving Health System Efficiency: Achieving Better Value for Money. Brussels: Joint European Commis- sion/OECD Conference.
5. Dubois, D. J. (2010). Grand challenges in pharmacoeconomics and health outcomes. Front. Pharmacol. 1:7. doi:10.3389/fphar.2010.00007
6. European Commission. (1989). Council Directive 89/105/EEC of 21 December 1988 Relating to the Transparencyof Measures Regulating the Prices of Medicinal Products for Human Use and their Inclusion in the Scope of National Health Insurance Sys- tems, European Commission: Brus- sels, 8-11.
7. European Commission. (2005). Phar- maceutical Forum. Available at: http://ec.europa.eu/pharmaforum/
8. European Medicines Agency. (2009). Report on Workshop on the Devel- opment of an EMEA Transparency Policy. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2009/10/WC500005 270.pdf
9. International Society for Pharmacoeco- nomics and Outcomes Research (ISPOR). (2011). ISPOR Tools for Health Care Decision Makers. Avail- able at: http://www.ispor.org/work.paper/UseOfResearch_index.asp
10. Kristensen, F. B., Lampe, K., Chase, D. L., Lee-Robin, S. H., Wild, C., Moharra, M., Garrido, M. V., Nielsen, C. P., Røttingen, J. A., Neik- ter, S. A., Bistrup, M. L., and The European Network for Health Tech- nology Assessment. (2009). Practi- cal tools and methods for health technology assessment in Europe: structures, methodologies, and tools developed by the European network for health technology assessment. Int. J. Technol. Assess. Health Care 25, 1-8.
11. Lampe, K., Mäkelä, M., Garrido, M. V., Anttila, H., Autti-Rämö, I., Hicks, N. J., Hofmann, B., Koivisto, J., Kunz, R., Kärki, P., Malmi- vaara, A., Meiesaar, K., Reiman- Möttönen,P.,Norderhaug,I.,Paster- nack, I., Ruano-Ravina, A., Räsä- nen,P.,Saalasti-Koskinen,U.,Saarni, S. I., Walin, L., Kristensen, F. B., and The European Network for Health Technology Assessment. (2009). The HTA core model: a novel method for producing and report- ing health technology assessments. Int. J. Technol. Assess. Health Care 25, 9-20.
12. National Institute for Health and Clini- cal Excellence. (2005). NICE Citizens Council Report Ultra Orphan Drugs. Available at: http://www.nice.org.uk/niceMedia/pdf/boardmeeting/brdjan05item4.pdf
13. National Institute for Health and Clinical Excellence. (2007). Final Appraisal Determination - Borte- zomib Monotherapy for Relapsed Multiple Myeloma. Available at: http://www.nice.org.uk/guidance/index.jsp?action = folder&r = true& o = 35152
14. O'Donnell, J. C., Pham, S. V., Pashos, C. L., Miller, D. W., and Smith, M. D. (2009). Health technology assess- ment: lessons learned from around theworld-anoverview.Value Health 12(Suppl. 2), S1-S5.
15. Raftery, J. (2006). Review of NICE's recommendations, 1999-2005. BMJ 332, 1266-1268.
16. Raftery, J. (2010). Multiple sclerosis risk sharing scheme: a costly failure. BMJ 340, c1672.
17. Rawlins, M. D., and Culyer, A. J. (2004). National Institute for Clinical Excel- lence and its value judgments. BMJ 329, 224-227.
18. Sorenson, C., Drummond, M., and Kanavos, P. (2008). Ensuring Value for Money in Health Care: The Role of HTA in the European Union. Copenhagen: European Obser- vatory on Health Systems and Policies.
19. Sudlow, C., and Counsell, C. (2003). Problems with the UK Government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 326, 383-392.
20. Tilson, L., and Barry, M. (2010). Recent developments in pharmacoeconomic evaluation in Ireland. Expert Rev. Pharmacoecon. Outcomes Res. 10, 221-224.
21. Van Wilder, P., and Dupont, A. (2008). Introducing evidence- based medicine in reimbursement procedures: does it affect the outcome? Value Health 11, 784-787.
22. Webb, D. (2009). Early Assessment of Cost-Effectiveness. Edinburgh: Congress of the European Association for Clinical Pharmacology and Therapeutics.